文献速递淋巴瘤

意大利淋巴瘤基金会队列研究:R-COMP与R-CHOP在老年弥漫性大B细胞淋巴瘤患者中的比较

A Fondazione Italiana Linfomi cohort study of R-COMP vs R-CHOP in older patients with diffuse large B-cell lymphoma.
PubMed 文献 · Blood Adv · 2023-01-01

该前瞻性队列纳入意大利淋巴瘤基金会老年项目中的≥65岁弥漫性大B细胞淋巴瘤患者,按当地实践接受全剂量R-CHOP或R-COMP。R-COMP组患者更老、体能状态更差、基线心脏疾病更多。两组3年无进展生存率和总生存率相似,R-CHOP仅在EPI低危组中无进展生存更优。作者建议R-COMP可用于中高危EPI老年患者,R-CHOP仍是低危患者的标准治疗。

要点

  • R-COMP组患者中位年龄76岁,R-CHOP组71岁。
  • R-COMP组体能状态良好者61%,R-CHOP组88%(P < .001)。
  • R-CHOP仅在EPI低危组中无进展生存优于R-COMP。

核心结论

  • 作者建议R-COMP是中高危EPI老年DLBCL患者的潜在治愈性治疗,即使存在基线心脏病。
  • R-CHOP被确认为低危患者的标准治疗。

研究设计与样本

  • 前瞻性队列研究,纳入意大利淋巴瘤基金会老年项目中≥65岁的DLBCL患者,按当地实践接受全剂量R-CHOP或R-COMP。
  • 起始1163例患者中,383例(55%)接受R-CHOP,308例(45%)接受R-COMP。

主要发现

  • R-COMP组较R-CHOP组年龄更大(中位76 vs 71岁),简化老年评估体能良好者更少(61% vs 88%;P < .001),基线心脏疾病(>1级)更多(32% vs 8%;P < .001)。
  • R-CHOP与R-COMP的3年无进展生存率相似(70% vs 64%),3年总生存率分别为77% vs 71%。
  • 仅在EPI低危组中,R-CHOP较R-COMP与更好的无进展生存相关。
  • 两组因毒性中断治疗或心脏事件的发生率相似(P = 1.00)。

临床怎么用

  • 作者建议R-COMP可用于中危或高危EPI的老年DLBCL患者,即使存在基线心脏病。
  • 作者确认R-CHOP是低危患者的标准治疗。
  • 原文未据此给出其他推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) is the most commonly used regimen for the upfront treatment of diffuse large B-cell lymphoma (DLBCL). However, it is associated with cardiotoxicity, especially in older patients. Substituting doxorubicin with non-PEGylated liposomal doxorubicin (R-COMP) may reduce the risk of cardiac events, but its efficacy has never been demonstrated in prospective trials. We describe the characteristics and outcome of patients with DLBCL aged ≥65 years prospectively enrolled in the Elderly Project by the Fondazione Italiana Linfomi and treated with full doses of R-CHOP or R-COMP per local practice. Starting from 1163 patients, 383 (55%) were treated with R-CHOP and 308 (45%) with R-COMP. Patients treated with R-COMP were older (median age, 76 vs 71 years), less frequently fit at simplified geriatric assessment (61% vs 88%; P < .001), and had a more frequent baseline cardiac disorders (grade >1, 32% vs 8%; P < .001). Three-year progression-free survival (PFS) was similar between R-CHOP and R-COMP (70% and 64%); 3-year overall survival was 77%, and 71% respectively. R-CHOP was associated with better PFS vs R-COMP only in the Elderly Prognostic Index (EPI) low-risk group. The two groups had similar rates of treatment interruptions due to toxicities or of cardiac events (P = 1.00). We suggest R-COMP is a potentially curative treatment for older patients with intermediate- or high-risk EPI, even in the presence of a baseline cardiopathy. R-CHOP is confirmed as the standard therapy for low risk patients.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Arcari A, Rigacci L, Tucci A, et al. A Fondazione Italiana Linfomi cohort study of R-COMP vs R-CHOP in older patients with diffuse large B-cell lymphoma. Blood Adv. 2023. PMID: 37276080. doi:10.1182/bloodadvances.2023009839

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。